Company profile
Viracta Therapeutics, Inc.
OTC: VIRX · Healthcare · Biotechnology
PublicHQ Cardiff-by-the-Sea, CACIK 0001061027Reports USD
#1032 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 57GM —SS 49
v0.1 · 25/100 weight · pillars only
↑ disclosure history, listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$738.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$51.1M
Employees
26
as of 2026-08-27
Market cap
$388.7k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$120.0k$120.0k2020
Net income-$51.1M-$51.1M2023
Operating income-$50.7M-$50.7M2023
Total assets$56.7M$56.7M2023
Liabilities$38.4M$38.4M2023
Equity$18.3M$18.3M2023
Revenue trend
FY2016 – FY2020 · USD
FY16
FY16
FY16
FY17
FY18
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Viracta Therapeutics, Inc.’s revenue?
Viracta Therapeutics, Inc. booked $120.0k in FY2020 revenue, contracting 94% year over year — among the slowest-growing Healthcare companies we track, at a -42548.3% net margin.
Peers · Healthcare
Ainos, Inc.41DAdvanced BioMedical Technologies Inc.——AI/ML Innovations Inc.——Soligenix, Inc.42DMicrobot Medical Inc.54DBullfrog AI Holdings, Inc. Common Stock30DKey facts
CEOCraig R. Jalbert
SectorHealthcare
IndustryBiotechnology
HeadquartersCardiff-by-the-Sea, CA
ExchangeOTC: VIRX
Employees26
IPO date2005-09-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.